{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:28:23Z","timestamp":1786771703780,"version":"build-2736575974"},"reference-count":89,"publisher":"The Fukushima Society of Medical Science","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5387\/fms.26-00034","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:10:44Z","timestamp":1786572644000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and pathophysiological roles of YKL-40 in obstructive airway diseases"],"prefix":"10.5387","author":[{"given":"Yasuhito","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Porsbjerg C, Mel\u00e9n E, Lehtim\u00e4ki L, Shaw D. Asthma. Lancet, <b>401<\/b>(10379): 858-873, 2023.","DOI":"10.1016\/S0140-6736(22)02125-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Agust\u00ed A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet, <b>390<\/b>(10098): 980-987, 2017.","DOI":"10.1016\/S0140-6736(17)32136-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liu T, Woodruff PG, Zhou X. Advances in non-type 2 severe asthma : from molecular insights to novel treatment strategies. Eur Respir J, <b>64<\/b>(2), 2024.","DOI":"10.1183\/13993003.00826-2023"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gauvreau GM, White L, Davis BE. Anti-alarmin approaches entering clinical trials. Curr Opin Pulm Med, <b>26<\/b>(1): 69-76, 2020.","DOI":"10.1097\/MCP.0000000000000615"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. Front Immunol, <b>15<\/b>: 1404615, 2024.","DOI":"10.3389\/fimmu.2024.1404615"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hizawa N. Common Pathogeneses Underlying Asthma and Chronic Obstructive Pulmonary Disease -Insights from Genetic Studies. Int J Chron Obstruct Pulmon Dis, <b>19<\/b>: 633-642, 2024.","DOI":"10.2147\/COPD.S441992"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD : predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J, <b>27<\/b>(5): 964-971, 2006.","DOI":"10.1183\/09031936.06.00072105"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Takayama Y, Ohnishi H, Ogasawara F, Oyama K, Kubota T, Yokoyama A. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis, <b>13<\/b>: 2525-2532, 2018.","DOI":"10.2147\/COPD.S167600"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics, <b>43<\/b>(2): 221-225, 1997.","DOI":"10.1006\/geno.1997.4778"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ober C, Chupp GL. The chitinase and chitinase-like proteins : a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol, <b>9<\/b>(5): 401-408, 2009.","DOI":"10.1097\/ACI.0b013e3283306533"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Renkema GH, Boot RG, Au FL, <i>et al.<\/i> Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem, <b>251<\/b>(1-2): 504-509, 1998.","DOI":"10.1046\/j.1432-1327.1998.2510504.x"},{"key":"12","unstructured":"12. Volck B, Price PA, Johansen JS, <i>et al.<\/i> YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians, <b>110<\/b>(4): 351-360, 1998."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res, <b>250<\/b>(1): 168-173, 1999.","DOI":"10.1006\/excr.1999.4511"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Park JA, Drazen JM, Tschumperlin DJ. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J Biol Chem, <b>285<\/b>(39): 29817-29825, 2010.","DOI":"10.1074\/jbc.M110.103416"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tang H, Sun Y, Shi Z, <i>et al.<\/i> YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-kappaB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol, <b>190<\/b>(1): 438-446, 2013.","DOI":"10.4049\/jimmunol.1201827"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lai T, Wu D, Chen M, <i>et al.<\/i> YKL-40 expression in chronic obstructive pulmonary disease : relation to acute exacerbations and airway remodeling. Respir Res, <b>17<\/b>: 31, 2016.","DOI":"10.1186\/s12931-016-0338-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Majewski S, Tworek D, Szewczyk K, <i>et al.<\/i> Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, <b>14<\/b>: 1611-1631, 2019.","DOI":"10.2147\/COPD.S184097"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chupp GL, Lee CG, Jarjour N, <i>et al.<\/i> A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med, <b>357<\/b>(20): 2016-2027, 2007.","DOI":"10.1056\/NEJMoa073600"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. L\u00e9tuv\u00e9 S, Kozhich A, Arouche N, <i>et al.<\/i> YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol, <b>181<\/b>(7): 5167-5173, 2008.","DOI":"10.4049\/jimmunol.181.7.5167"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Liu L, Zhang X, Liu Y, <i>et al.<\/i> Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respir Res, <b>20<\/b>(1): 95, 2019.","DOI":"10.1186\/s12931-019-1051-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. James AJ, Reinius LE, Verhoek M, <i>et al.<\/i> Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, <b>193<\/b>(2): 131-142, 2016.","DOI":"10.1164\/rccm.201504-0760OC"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gon Y, Maruoka S, Ito R, <i>et al.<\/i> Utility of serum YKL-40 levels for identification of patients with asthma and COPD. Allergol Int, <b>66<\/b>(4): 624-626, 2017.","DOI":"10.1016\/j.alit.2017.02.010"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shirai T, Hirai K, Gon Y, <i>et al.<\/i> Combined Assessment of Serum Periostin and YKL-40 May Identify Asthma-COPD Overlap. J Allergy Clin Immunol Pract, <b>7<\/b>(1): 134-145.e1, 2019.","DOI":"10.1016\/j.jaip.2018.06.015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Otsuka K, Matsumoto H, Niimi A, <i>et al.<\/i> Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration, <b>83<\/b>(6): 507-519, 2012.","DOI":"10.1159\/000330840"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gao J, Iwamoto H, Koskela J, <i>et al.<\/i> Characterization of sputum biomarkers for asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis, <b>11<\/b>: 2457-2465, 2016.","DOI":"10.2147\/COPD.S113484"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hinks TSC, Brown T, Lau LCK, <i>et al.<\/i> Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol, <b>138<\/b>(1): 61-75, 2016.","DOI":"10.1016\/j.jaci.2015.11.020"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ilmarinen P, Tuomisto LE, Niemel\u00e4 O, H\u00e4m\u00e4l\u00e4inen M, Moilanen E, Kankaanranta H. YKL-40 and adult-onset asthma : Elevated levels in clusters with poorest outcome. J Allergy Clin Immunol Pract, <b>7<\/b>(7): 2466-2468.e3, 2019.","DOI":"10.1016\/j.jaip.2019.03.043"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kunz LI, van\u2019t Wout EF, van Schadewijk A, <i>et al.<\/i> Regulation of YKL-40 expression by corticosteroids : effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo. Respir Res, <b>16<\/b>: 154, 2015.","DOI":"10.1186\/s12931-015-0314-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gumus A, Kayhan S, Cinarka H, <i>et al.<\/i> High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity. Tohoku J Exp Med, <b>229<\/b>(2): 163-170, 2013.","DOI":"10.1620\/tjem.229.163"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kimura H, Shimizu K, Tanabe N, <i>et al.<\/i> Further evidence for association of YKL-40 with severe asthma airway remodeling. Ann Allergy Asthma Immunol, <b>128<\/b>(6): 682-688.e5, 2022.","DOI":"10.1016\/j.anai.2022.03.016"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Konradsen JR, James A, Nordlund B, <i>et al.<\/i> The chitinase-like protein YKL-40 : a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol, <b>132<\/b>(2): 328-335.e5, 2013.","DOI":"10.1016\/j.jaci.2013.03.003"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Tang H, Sun Y, Shi Z, <i>et al.<\/i> YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-\u03baB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol, <b>190<\/b>(1): 438-446, 2013.","DOI":"10.4049\/jimmunol.1201827"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zhu Y, Huang B, Jiang G. Correlation between changes in serum YKL-40, LXRs, PPM1A, and TGF-\u03b21 levels and airway remodeling and lung function in patients with bronchial asthma. J Asthma, <b>61<\/b>(7): 698-706, 2024.","DOI":"10.1080\/02770903.2023.2301426"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Guan R, Lin R, Jin R, <i>et al.<\/i> Chitinase-like protein YKL-40 regulates human bronchial epithelial cells proliferation, apoptosis, and migration through TGF-\u03b21\/Smads pathway. Hum Exp Toxicol, <b>39<\/b>(4): 451-463, 2020.","DOI":"10.1177\/0960327119891218"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Huang QP, Xie ZF, Huang J. Assessment of the Association between Genetic Polymorphisms in the CHI3L1 Gene and Asthma Risk. Int Arch Allergy Immunol, <b>183<\/b>(8): 907-918, 2022.","DOI":"10.1159\/000522393"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Gomez JL, Crisafi GM, Holm CT, <i>et al.<\/i> Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. J Allergy Clin Immunol, <b>136<\/b>(1): 51-58.e10, 2015.","DOI":"10.1016\/j.jaci.2014.11.027"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Gomez JL, Yan X, Holm CT, <i>et al.<\/i> Characterisation of asthma subgroups associated with circulating YKL-40 levels. Eur Respir J, <b>50<\/b>(4), 2017.","DOI":"10.1183\/13993003.00800-2017"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Hansen JW, Thomsen SF, Porsbjerg C, <i>et al.<\/i> YKL-40 and genetic status of CHI3L1 in a large group of asthmatics. Eur Clin Respir J, <b>2<\/b>: 25117, 2015.","DOI":"10.3402\/ecrj.v2.25117"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tong X, Wang D, Liu S, <i>et al.<\/i> The YKL-40 protein is a potential biomarker for COPD : a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis, <b>13<\/b>: 409-418, 2018.","DOI":"10.2147\/COPD.S152655"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Suzuki Y, Saito J, Kikuchi M, <i>et al.<\/i> Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders. Allergol Int, <b>75<\/b>(1): 52-61, 2026.","DOI":"10.1016\/j.alit.2025.05.004"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res, <b>7<\/b>(5): 501-512, 1992.","DOI":"10.1002\/jbmr.5650070506"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Magnusdottir U, Yang Jonatansdottir Y, Oskarsson KR, Hjorleifsson JG, Einarsson JM, Thormodsson FR. Characterization of YKL-40 Binding to Extracellular Matrix Glycosaminoglycans. Mar Drugs, <b>23<\/b>(10), 2025.","DOI":"10.3390\/md23100379"},{"key":"43","unstructured":"43. Volck B, Price PA, Johansen JS, <i>et al.<\/i> YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians, <b>110<\/b>(4): 351-360, 1998."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Bara I, Ozier A, Girodet PO, <i>et al.<\/i> Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med, <b>185<\/b>(7): 715-722, 2012.","DOI":"10.1164\/rccm.201105-0915OC"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Sun X, Nakajima E, Norbrun C, <i>et al.<\/i> Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension. JCI Insight, <b>7<\/b>(18), 2022.","DOI":"10.1172\/jci.insight.159578"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem, <b>278<\/b>(39): 37753-37760, 2003.","DOI":"10.1074\/jbc.M303137200"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation, <b>7<\/b>: 34, 2010.","DOI":"10.1186\/1742-2094-7-34"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, <i>et al.<\/i> YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J Neuroinflammation, <b>14<\/b>(1): 118, 2017.","DOI":"10.1186\/s12974-017-0893-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Elias JA, Homer RJ, Hamid Q, Lee CG. Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol, <b>116<\/b>(3): 497-500, 2005.","DOI":"10.1016\/j.jaci.2005.06.028"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Lee CG, Hartl D, Lee GR, <i>et al.<\/i> Role of breast regression protein 39 (BRP-39)\/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med, <b>206<\/b>(5): 1149-1166, 2009.","DOI":"10.1084\/jem.20081271"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Kazakova MH, Batalov AZ, Mateva NG, Kolarov ZG, Sarafian VS. YKL-40 and cytokines - a New Diagnostic Constellation in Rheumatoid Arthritis? Folia Med (Plovdiv), <b>59<\/b>(1): 37-42, 2017.","DOI":"10.1515\/folmed-2017-0013"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. McDowell PJ, Azim A, Busby J, <i>et al.<\/i> Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma. J Allergy Clin Immunol, <b>156<\/b>(4): 911-922, 2025.","DOI":"10.1016\/j.jaci.2025.05.031"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Letuve S, Kozhich A, Arouche N, <i>et al.<\/i> YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol, <b>181<\/b>(7): 5167-5173, 2008.","DOI":"10.4049\/jimmunol.181.7.5167"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Park SJ, Jun YJ, Kim TH, <i>et al.<\/i> Increased expression of YKL-40 in mild and moderate\/severe persistent allergic rhinitis and its possible contribution to remodeling of nasal mucosa. Am J Rhinol Allergy, <b>27<\/b>(5): 372-380, 2013.","DOI":"10.2500\/ajra.2013.27.3941"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Sakazaki Y, Hoshino T, Takei S, <i>et al.<\/i> Overexpression of chitinase 3-like 1\/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD. PLoS One, <b>6<\/b>(9): e24177, 2011.","DOI":"10.1371\/journal.pone.0024177"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Sun Y, Shi Z, Liu B, <i>et al.<\/i> YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway. Cell Cycle, <b>19<\/b>(11): 1378-1390, 2020.","DOI":"10.1080\/15384101.2020.1750811"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. H\u00f8gdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, H\u00f8gdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest, <b>60<\/b>(4): 247-251, 2000.","DOI":"10.1080\/00365510050184886"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Perez MF, Atuegwu NC, Mortensen EM, Oncken C. The inflammatory biomarker YKL-40 is elevated in the serum, but not the sputum, of E-cigarette users. Exp Lung Res, <b>47<\/b>(2): 55-66, 2021.","DOI":"10.1080\/01902148.2020.1847216"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Przysucha N, G\u00f3rska K, Maskey-Warz\u0119chowska M, <i>et al.<\/i> The Role of Chitinases in Chronic Airway Inflammation Associated with Tobacco Smoke Exposure. Cells, <b>11<\/b>(23), 2022.","DOI":"10.3390\/cells11233765"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Song M, Zhang G, Shi H, Zhu E, Deng L, Shen H. Serum YKL-40 in coronary heart disease : linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events. Front Cardiovasc Med, <b>10<\/b>: 1242339, 2023.","DOI":"10.3389\/fcvm.2023.1242339"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kastrup J, Johansen JS, Winkel P, <i>et al.<\/i> High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J, <b>30<\/b>(9): 1066-1072, 2009.","DOI":"10.1093\/eurheartj\/ehp049"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Chou HH, Teng MS, Juang JJ, <i>et al.<\/i> Circulating YKL-40 levels but not CHI3L1 or TRIB1 gene variants predict long-term outcomes in patients with angiographically confirmed multivessel coronary artery disease. Sci Rep, <b>14<\/b>(1): 29416, 2024.","DOI":"10.1038\/s41598-024-81190-8"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Schroder J, Jakobsen JC, Winkel P, <i>et al.<\/i> Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. J Am Heart Assoc, <b>9<\/b>(5): e014634, 2020.","DOI":"10.1161\/JAHA.119.014634"},{"key":"64","unstructured":"64. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis : correlations between clinical and laborarory parameters. Clin Exp Rheumatol, <b>19<\/b>(6): 655-660, 2001."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. V\u00e4\u00e4n\u00e4nen T, Vuolteenaho K, Kautiainen H, <i>et al.<\/i> Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One, <b>12<\/b>(8): e0183294, 2017.","DOI":"10.1371\/journal.pone.0183294"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol, <b>38<\/b>(6): 599-605, 2003.","DOI":"10.1080\/00365520310000537"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Ahn SS, Yoon T, Park YB, <i>et al.<\/i> Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis : an observational study. Arthritis Res Ther, <b>23<\/b>(1): 77, 2021.","DOI":"10.1186\/s13075-021-02467-1"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis : A Literature Review and Update. J Clin Med, <b>9<\/b>(11), 2020.","DOI":"10.3390\/jcm9113388"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res, <b>55<\/b>(2): 53-59, 2006.","DOI":"10.1007\/s00011-005-0010-8"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Nielsen AR, Erikstrup C, Johansen JS, <i>et al.<\/i> Plasma YKL-40 : a BMI-independent marker of type 2 diabetes. Diabetes, <b>57<\/b>(11): 3078-3082, 2008.","DOI":"10.2337\/db08-0182"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. R\u00f8ndbjerg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol, <b>10<\/b>: 54, 2011.","DOI":"10.1186\/1475-2840-10-54"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Albeltagy ES, Abdul-Mohymen AM, Taha DRA. Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU : a pilot study. Int Urol Nephrol, <b>52<\/b>(2): 351-361, 2020.","DOI":"10.1007\/s11255-019-02364-2"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Vandenberghe W, De Loor J, Francois K, <i>et al.<\/i> Potential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery : A Prospective Cohort Study. Diagnostics (Basel), <b>13<\/b>(6), 2023.","DOI":"10.3390\/diagnostics13061047"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Conroy AL, Hawkes MT, Elphinstone R, <i>et al.<\/i> Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria. Malar J, <b>17<\/b>(1): 82, 2018.","DOI":"10.1186\/s12936-018-2225-5"},{"key":"75","unstructured":"75. Keskin GS, Helvac\u0131 \u00d6, Yayla \u00c7, <i>et al.<\/i> Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease. Turk J Med Sci, <b>49<\/b>(1): 139-146, 2019."},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Bi SH, Su C, A LT, Wang Y, He L, Zhang AH. YKL-40 (chitinase-3-like protein 1) serum levels are associated with abdominal aortic calcification in hemodialysis patients. Int Urol Nephrol, <b>56<\/b>(8): 2695-2703, 2024.","DOI":"10.1007\/s11255-024-03986-x"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Okyay GU, Er RE, Tekbudak MY, <i>et al.<\/i> Novel inflammatory marker in dialysis patients : YKL-40. Ther Apher Dial, <b>17<\/b>(2): 193-201, 2013.","DOI":"10.1111\/j.1744-9987.2012.01141.x"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Johansen JS, Christoffersen P, M\u00f8ller S, <i>et al.<\/i> Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol, <b>32<\/b>(6): 911-920, 2000.","DOI":"10.1016\/S0168-8278(00)80095-1"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Tao H, Yang JJ, Shi KH, <i>et al.<\/i> The significance of YKL-40 protein in liver fibrosis. Inflamm Res, <b>63<\/b>(4): 249-254, 2014.","DOI":"10.1007\/s00011-013-0698-9"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Kumagai E, Mano Y, Yoshio S, <i>et al.<\/i> Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep, <b>6<\/b>: 35282, 2016.","DOI":"10.1038\/srep35282"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Bla\u017eevi\u0107 N, Trkulja V, Rogi\u0107 D, <i>et al.<\/i> YKL-40 as a risk stratification marker in acute pancreatitis : A prospective study. Pancreatology, <b>25<\/b>(1): 48-57, 2025.","DOI":"10.1016\/j.pan.2024.11.024"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Hansen M, Nielsen AR, Vilsb\u00f8ll T, <i>et al.<\/i> Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. Pancreas, <b>41<\/b>(8): 1316-1318, 2012.","DOI":"10.1097\/MPA.0b013e31824d9b93"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Schultz NA, Christensen IJ, Werner J, <i>et al.<\/i> Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One, <b>8<\/b>(6): e67059, 2013.","DOI":"10.1371\/journal.pone.0067059"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Chen IM, Johansen AZ, Dehlendorff C, <i>et al.<\/i> Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev, <b>29<\/b>(1): 176-184, 2020.","DOI":"10.1158\/1055-9965.EPI-19-0672"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Johansen AZ, Novitski SI, Hjaltelin JX, <i>et al.<\/i> Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy. Front Immunol, <b>14<\/b>: 1228907, 2023.","DOI":"10.3389\/fimmu.2023.1228907"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Olsson B, Lautner R, Andreasson U, <i>et al.<\/i> CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease : a systematic review and meta-analysis. Lancet Neurol, <b>15<\/b>(7): 673-684, 2016.","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson\u2019s disease and atypical parkinsonian disorders. Sci Rep, <b>8<\/b>(1): 13276, 2018.","DOI":"10.1038\/s41598-018-31517-z"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Malmestr\u00f6m C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol, <b>269<\/b>(1-2): 87-89, 2014.","DOI":"10.1016\/j.jneuroim.2014.02.004"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Wang YY, Zhang M, Chen SJ, <i>et al.<\/i> Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer\u2019s disease, with hypertensive dependency. Front Aging Neurosci, <b>17<\/b>: 1630022, 2025.","DOI":"10.3389\/fnagi.2025.1630022"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00034\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:05:36Z","timestamp":1786770336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00034\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":89,"URL":"https:\/\/doi.org\/10.5387\/fms.26-00034","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26-00034"}}